Hepatitis C virus: A global view

doi:10.4254/wjh.v7.i26.2676

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 26

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12457)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

966

WORD

353

HTML

6738

Tables (1-2)

543

Sum=8600

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1572

Download

2332

Sum=3904

Nov 18, 2015 (publication date) through Mar 3, 2026

Times Cited of This Article

Times Cited (97)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Hepatol. Nov 18, 2015; 7(26): 2676-2680
Published online Nov 18, 2015. doi: 10.4254/wjh.v7.i26.2676

Hepatitis C virus: A global view

Amal Ahmed Mohamed, Tamer A Elbedewy, Magdy El-Serafy, Naglaa El-Toukhy, Wesam Ahmed, Zaniab Ali El Din

Amal Ahmed Mohamed, Biochemistry Department, National Hepatology and Tropical Medicine Institute, Cairo 11796, Egypt

Tamer A Elbedewy, Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta 31111, Egypt

Magdy El-Serafy, Tropical Department, National Hepatology and Tropical Medicine Institute; Cairo 11796, Egypt

Naglaa El-Toukhy, Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, Benha University, Banha 13511, Egypt

Wesam Ahmed, Zaniab Ali El Din, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt

Author contributions: All authors contributed equally to this work.

Conflict-of-interest statement: There is no conflict of interest.

Correspondence to: Dr. Amal Ahmed Mohamed, Consultant of Biochemistry and Molecular Biology, Biochemistry Department, National Hepatology and Tropical Medicine Institute, Fom El-Khalig, Cairo 11796, Egypt. amalahmedhcp@yahoo.com

Telephone: +20-12-24847367

Received: September 9, 2014
Peer-review started: September 9, 2014
First decision: September 28, 2014
Revised: July 29, 2015
Accepted: November 3, 2015
Article in press: November 4, 2015
Published online: November 18, 2015
Processing time: 434 Days and 23.1 Hours

Abstract

Hepatitis C virus (HCV) is a global challenge; 130-175 million are chronically infected. Over 350000 die each year from HCV. Chronic HCV is the primary cause of cirrhosis, hepatocellular carcinoma (HCC), and end-stage liver disease. Management of chronic HCV is aimed at preventing cirrhosis, reducing the risk of HCC, and treating extra hepatic complications. New treatments for chronic HCV has been devoted based on direct-acting antivirals, as pegylated interferon (peginterferon) is responsible for many side effects and limits treatment access. Sofosbuvir is the first compound to enter the market with Peginterferon-free combination regimens.

Keywords: Hepatitis C; Peginterferon; Sofosbuvir; Direct-acting antivirals

Core tip: Peginterferon is responsible for many side effects. Direct-acting antiviral drugs represent a breakthrough in hepatitis C virus (HCV) therapy. Sofosbuvir is the first compound to enter the market with Peginterferon-free combination regimens. The next few years are expected to introduce more new drugs in the market of HCV therapy with complete elimination of pegylated interferon and ribavirin combination therapy.